col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Springer-Verlag: European Journal of Clinical Pharmacology
  original article Date Title Authors   All Authors
1 [GO] 2021―Aug―30 Restrictions on the use of placebo in new COVID-19 vaccine trials Maurizio Bonati
2 [GO] 2021―Aug―24 Correction to: Calling for an exponential escalation scheme in vaccine development for COVID-19 Martin Wehling
3 [GO] 2021―Aug―07 Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal Beatrice Bouhanick, François Montastruc, Samuel Tessier, Clara Brusq, Vanina Bongard, Jean-Michel Senard, et al. (+2)
4 [GO] 2021―May―12 Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis Massimo Tempestilli, Giulia Valeria Stazi, Gaetano Maffongelli, Maria Cristina Marini, Tommaso Ascoli Bartoli, Giuseppe Ippolito, et al. (+3)
5 [GO] 2021―Apr―25 Correction to: Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19 Suzy Huijghebaert, Levi Hoste, Guido Vanham
6 [GO] 2021―Mar―27 Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19 Huijghebaert Suzy, Hoste Levi, Vanham Guido
7 [GO] 2021―Mar―17 Correction to: Iron chelation may harm patients with COVID-19 Michael D. Garrick, Andrew J. Ghio
8 [GO] 2021―Mar―04 Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19 Nils von Hentig
9 [GO] 2021―Feb―02 The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials Chia Siang Kow, Syed Shahzad Hasan
10 [GO] 2021―Jan―06 Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing Vladimir Trkulja
11 [GO] 2021―Jan―03 ACE inhibitor-related angioedema in a COVID-19 patient-a plausible contribution of the viral infection? Michał Kuzemczak, Charalampos Kavvouras, Mohammad Alkhalil, Mark Osten
12 [GO] 2020―Nov―26 Reply to the letter to the Editor “Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts” Nicolas Simon, Jean Claude Alvarez
13 [GO] 2020―Nov―25 Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts Dario Cattaneo, Mario Corbellino, Cristina Gervasoni
14 [GO] 2020―Nov―13 Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients Xueting Yao, Xiaoyu Yan, Xiaohan Wang, Ting Cai, Shun Zhang, Cheng Cui, et al. (+7)
15 [GO] 2020―Oct―13 Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients Jean Claude Alvarez, Pierre Moine, Benjamin Davido, Isabelle Etting, Djillali Annane, Islam Amine Larabi, Nicolas Simon
16 [GO] 2020―Oct―13 Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies Meng Zhao, Jieyu Lu, Yihu Tang, Yawei Dai, Jingxin Zhou, Yanhu Wu
17 [GO] 2020―Oct―04 Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 Chia Siang Kow, Mamoon Aldeyab, Syed Shahzad Hasan
18 [GO] 2020―Sep―01 Iron chelation may harm patients with COVID-19 Michael D. Garrick, Andrew J. Ghio
19 [GO] 2020―Sep―01 Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19 Qibo Fu, Xiao Zheng, Yunlian Zhou, Lanfang Tang, Zhimin Chen, Shaoqing Ni
20 [GO] 2020―Sep―01 Reply: Iron chelation may harm patients with COVID-19 Anis Abobaker
21 [GO] 2020―Aug―11 Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials Can Chen, Kunming Pan, Bingjie Wu, Xiaoye Li, Zhangzhang Chen, Qing Xu, et al. (+2)
22 [GO] 2020―Jul―21 Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies Georgia Ragia, Vangelis G. Manolopoulos
23 [GO] 2020―Jun―30 Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome? Anis Abobaker
24 [GO] 2020―Jun―28 The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 Francesco Ferrara, Giovanni Granata, Chiara Pelliccia, Raffaele La Porta, Antonio Vitiello
25 [GO] 2020―Jun―25 What about COVID-19 and arachidonic acid pathway? Malvina Hoxha
26 [GO] 2020―Jun―16 Calling for an exponential escalation scheme in vaccine development for COVID-19 Martin Wehling


[de][en]

Last change 2021―Sep―04 16:13:39 UTC

© Daten-Quadrat 2021       Done in 0.009 sec